Latest Breaking News On - Giacomo chiesi - Page 8 : comparemela.com

Chiesi Global Rare Diseases Announces Approval of FERRIPROX™ MR Deferiprone Extended-Release Tablets in Canada

New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy.

United kingdomUnited statesAdam daleyGiacomo chiesiBerry company public relationsB corpChiesi groupHealth canadaGlobal rare diseasesChiesi global rareMore informationProduct monographBenefit corporationGlobal rare

Chiesi Global Rare Diseases Announces Approval of FERRIPROX™ MR Deferiprone Extended-Release Tablets in Canada

/PRNewswire/ Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected.

United kingdomUnited statesGiacomo chiesiAdam daleyHealth canadaB corpBerry company public relationsChiesi groupGlobal rare diseasesChiesi global rareMore informationProduct monographBenefit corporationGlobal rare

Protalix and Chiesi gain positive opinion for pegunigalsidase alfa

The therapy becomes the first pegylated enzyme for the treatment of adult patients with Fabry disease - News - PharmaTimes

Derralynn hughesGiacomo chiesiUniversity college londonProtalix biotherapeuticsEuropean medicines agencyChiesi groupEuropean commissionCommittee for medicinal products human useGlobal rare diseasesMedicinal productsHuman useChiesi global rare diseases

CHMP recommends first pegylated enzyme for Fabry disease

A PEGylated enzyme replacement therapy for Fabry disease has received a positive opinion from the EMA's human medicines committee.

Dror bashanGiacomo chiesiProtalix biotherapeuticsEuropean medicines agencyEuropean commissionCommittee for medicinal products human useMedicinal productsHuman useChief executive officerChiesi global rare diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics (PLX) Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

Chiesi Global Rare Diseases and Protalix BioTherapeutics (PLX) Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGiacomo chiesiProtalix biotherapeutics incEuropean medicines agencyChiesi groupCommittee for medicinal products human useGlobal rare diseasesMedicinal productsHuman useChiesi global rare